insight
← 뒤로

Iatrogenic botulism: a risk for botulinum toxin's medical use?

Journal of neural transmission (Vienna, Austria : 1996) 2026

Dressler D, Frevert J, Johnson EA, Fink K, Pellett S, Pandey S, Walter U, Tacik P, Kanovsky P, Shahidi GA, Brüggemann N, Rosales RL, Relja M, Jin L, Rodriguez JAS, Pan L, Francisco GE, Shang H, Bai X, Adib Saberi F

원문 ↗ DOI ↗

관련 도메인

보툴리눔독소 주사 Botulinum Toxin Injection

Abstract

Botulinum toxin (BT) is infamous for its extreme toxicity. If it enters the bloodstream, it can cause botulism presenting with a typical pattern of motor and autonomic dysfunction. An international expert panel organised by IAB-Interdisciplinary Working Group for Movement Disorders explored iatrogenic botulism after BT's medical use (IB), reached conclusions and formulated recommendations. When injected into its target tissue, BT binds to gangliosides on cholinergic nerve terminals before it is internalised permanently. Small amounts of BT, however, are circulating within the bloodstream. When BT type B is applied, IB-B occurs frequently, typically affecting the autonomic nervous system. When BT type A is applied, IB-A only occurs in special circumstances, even when high doses are used. We identified 236 patients with IB-A in the literature. All IB-A was mild or moderate and fully reversible. In 212 patients, it occurred with unapproved BT use. In 116 of them, unapproved BT preparations were used, in 81, unapproved indications were treated and in 15, underlying neuromuscular impairment including myasthenia gravis, Lambert-Eaton myasthenic syndrome, amyotrophic lateral sclerosis and spinal muscle atrophy were contraindications for BT use. In 24 patients, IB-A occurred in approved BT use. Their evaluation was frequently incomplete, so that causes for IB-A often remain unclear. They may include presence of differential diagnosis, subclinical neuromuscular impairment and interference with additional diseases. When IB is suspected, proper evaluation is necessary to verify it and to identify its causes. Off-label use is common in BT therapy. However, it should be performed with caution, especially in children and when high doses are applied. High BT doses should not be applied to low volumes of target tissues, in order not to exceed the BT binding capacity.

추출된 의학 개체 (NER)

유형영어 표현한국어 / 풀이UMLS CUI출처등장
시술 botulinum toxin 보툴리눔독소 주사 dict 2
해부 neuromuscular scispacy 1
해부 spinal muscle scispacy 1
해부 tissues scispacy 1
해부 tissue scispacy 1
해부 cholinergic nerve terminals scispacy 1
해부 IB-B scispacy 1
해부 autonomic nervous system scispacy 1
합병증 bloodstream scispacy 1
약물 BT type B scispacy 1
약물 BT type A scispacy 1
질환 gravis scispacy 1
질환 botulism C0006057
Botulism
 scispacy 1
질환 toxicity C0040539
Toxicity aspects
 scispacy 1
질환 neuromuscular impairment scispacy 1
질환 myasthenia gravis C0026896
Myasthenia Gravis
 scispacy 1
질환 myasthenic syndrome C0022972
Lambert-Eaton Myasthenic Syndrome
 scispacy 1
질환 amyotrophic lateral sclerosis C0002736
Amyotrophic Lateral Sclerosis
 scispacy 1
질환 muscle atrophy C0026846
Muscular Atrophy
 scispacy 1
기타 patients scispacy 1
기타 amyotrophic lateral scispacy 1
기타 neuromuscular scispacy 1
기타 children scispacy 1
기타 BT type B scispacy 1
기타 BT type scispacy 1

📑 인용 관계

이 논문이 참조한 문헌 39

외부 PMID 30건 (DB 미수집)

🔗 함께 등장하는 도메인

이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들

필러 주입술 (21) 안검성형술 (14) 유방 (10) 안면거상술 (10) 지방흡입 (9) 코성형술 (8) 히알루론산 (7) 유방성형술 (6)

관련 논문